An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 03 Oct 2013 New trial record